5.22
price up icon8.07%   0.39
pre-market  プレマーケット:  5.23   0.01   +0.19%
loading
前日終値:
$4.83
開ける:
$5
24時間の取引高:
22.78M
Relative Volume:
1.00
時価総額:
$2.22B
収益:
$64.60M
当期純損益:
$-377.75M
株価収益率:
-3.3677
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
+7.85%
1か月 パフォーマンス:
+27.94%
6か月 パフォーマンス:
-27.90%
1年 パフォーマンス:
-44.11%
1日の値動き範囲:
Value
$4.99
$5.305
1週間の範囲:
Value
$4.72
$5.355
52週間の値動き範囲:
Value
$3.79
$12.36

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name
名前
Recursion Pharmaceuticals Inc
Name
セクター
Healthcare (1170)
Name
電話
(385) 269-0203
Name
住所
41S RIO GRANDE STREET, SALT LAKE CITY
Name
職員
800
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
RXRX's Discussions on Twitter

RXRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RXRX
Recursion Pharmaceuticals Inc
5.22 2.22B 64.60M -377.75M -335.64M -1.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-05-22 開始されました Morgan Stanley Equal-Weight
2023-03-16 開始されました Needham Buy
2022-09-16 開始されました KeyBanc Capital Markets Overweight
2022-04-18 ダウングレード BofA Securities Buy → Neutral
2022-03-04 ダウングレード SVB Leerink Outperform → Mkt Perform
2021-09-21 開始されました Berenberg Buy
2021-05-11 開始されました BofA Securities Buy
2021-05-11 開始されました Goldman Neutral
2021-05-11 開始されました JP Morgan Neutral
2021-05-11 開始されました KeyBanc Capital Markets Overweight
2021-05-11 開始されました SVB Leerink Outperform
すべてを表示

Recursion Pharmaceuticals Inc (RXRX) 最新ニュース

pulisher
Jun 18, 2025

Recursion Pharmaceuticals stockholders elect three Class I directors - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

Recursion Pharmaceuticals stockholders elect three Class I directors By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Recursion Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 16, 2025

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals (RXRX): Morgan Stanley Adjusts Price Target | RXRX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharma to reduce workforce by 20% - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Why Recursion Pharmaceuticals Stock Is Plummeting Today - AOL.com

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? - MSN

Jun 16, 2025
pulisher
Jun 15, 2025

Why Recursion Pharmaceuticals RXRX Could Be the NVDA of Biotech for NASDAQ:RXRX by TopgOptions - TradingView

Jun 15, 2025
pulisher
Jun 14, 2025

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Cautious Outlook on Recursion Pharmaceuticals Amid Strategic Restructuring and Cash Management Challenges - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Insmed surges on lung drug data; Recursion cuts staff - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable (NASDAQ:RXRX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion to lay off 20% of workforce amid biotech funding woes - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

After pipeline cull, AI drug developer Recursion cuts staff by 20% - FirstWord Pharma

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets - Genetic Engineering and Biotechnology News

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Benzinga

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Downsizes by 20% To Boost Cash Position - BioSpace

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion lays off 20% of staff in wake of pipeline cutbacks - Fierce Biotech

Jun 10, 2025
pulisher
Jun 10, 2025

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky (RXRX) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027 - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development - Value The Markets

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals (RXRX) Implements Workforce and Operat - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Announces Workforce Reduction Strategy - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals announces 20% workforce reduction - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Announces Personnel And Infrastructure ReductionSEC Filing - marketscreener.com

Jun 10, 2025
pulisher
Jun 08, 2025

15 Stocks That Stole The Show Last Week - Insider Monkey

Jun 08, 2025
pulisher
Jun 07, 2025

Recursion rises on launch of Boltz-2 in partnership with MIT - MSN

Jun 07, 2025
pulisher
Jun 07, 2025

Why Recursion Pharmaceuticals (RXRX) Soared On Friday - Insider Monkey

Jun 07, 2025
pulisher
Jun 06, 2025

10 Stocks Are Dominating Like Wall Street Titans - Insider Monkey

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:RXRX - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas - mx.advfn.com

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals shares surge on AI model release By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals shares surge on AI model release - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals (RXRX) Sees Surge in Bullish Options Activity | RXRX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion (RXRX) Shares Jump on New Biomolecular Model Launch - GuruFocus

Jun 06, 2025

Recursion Pharmaceuticals Inc (RXRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
大文字化:     |  ボリューム (24 時間):